Background Blood lipid concentrations are causally related to the risk of coronary heart disease (CHD). Various associations between CHD risk and genes that moderately affect plasma lipid levels have been described, but previous studies have typically involved too few 'cases' to assess these associations reliably.
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Methods
The present study involves 4685 cases of myocardial infarction (MI) and 3460 unrelated controls without diagnosed cardiovascular disease. Six polymorphisms of four 'lipid-related' genes were genotyped.
Results
For the apolipoprotein E ε2/ε3/ε4 polymorphism, the average increase in the plasma ratio of apolipoprotein B to apolipoprotein A 1 (apoB/apoA 1 ratio) among controls was 0.082 (s.e. 0.007) per stepwise change from ε3/ε2 to ε3/ε3 to ε3/ε4 genotype (trend P Ͻ 0.0001). The case-control comparison yielded a risk ratio for MI of 1.16 (95% CI: 1.06, 1.27; P = 0.001) per stepwise change in these genotypes. But, this risk ratio was not as extreme as would have been expected from the corresponding differences in plasma apoB/apoA 1 ratio between genotypes. Hence, following adjustment for the measured level of the plasma apoB/apoA 1 ratio, the direction of the risk ratio per stepwise change reversed to 0.83 (95% CI: 0.74, 0.92; P Ͻ 0.001). Similarly, for the apolipoprotein B Asn4311Ser and Thr71Ile polymorphisms, genotypes associated with more adverse plasma apolipoprotein concentrations were associated with significantly lower risk of MI after adjustment for the apoB/apoA 1 ratio. The B2 allele of the cholesteryl ester transfer protein TaqIb polymorphism was associated with a significantly lower plasma apoB/apoA 1 ratio, but with no significant difference in the risk of MI. Finally, the lipoprotein lipase Asn291Ser and T4509C (PvuII) polymorphisms did not produce clear effects on either the plasma apoB/apoA 1 ratio or the risk of MI.
Genetic factors that affect blood lipids may have either a greater or a lesser than expected effect on vascular disease risk if lifelong differences in blood lipids have a greater or lesser effect on disease than is seen in epidemiological studies of adults, or if those genetic factors also affect other disease mechanisms. If the effects of a particular genetic polymorphism on disease risk are not large, then although studies of only moderate size may well suffice to assess reliably the effects of genotype on blood lipids (the 'intermediate phenotype'), they will not suffice to assess reliably the effects of genotype on disease risk. For genetic polymorphisms that have only moderate effects on blood lipids (so that the means of the values for people with different genotypes all lie well within the normal range of values), reliable direct evidence of whether the effects on risk are appreciably greater or lesser than expected requires studies that involve much larger numbers of cases of vascular disease than is currently customary. 1 The two main plasma lipid fractions have opposite effects on the incidence of coronary heart disease (CHD): low-density lipoprotein (LDL) particles, which carry an apolipoprotein B (ApoB) molecule on their surface, are atherogenic; whereas high-density lipoprotein (HDL) particles, which carry an apolipoprotein A 1 (ApoA 1 ) molecule on their surface, are cardioprotective. Consequently, the ratio (ApoB/ApoA 1 ) of these plasma apolipoprotein levels is a very strong predictor of CHD rates. 2 Some genetic polymorphisms have been identified that have a moderate but definite effect on plasma lipid levels, and hence on the apoB/apoA 1 ratio. But, although many studies have investigated the relationship between polymorphisms of some such 'lipid-related' candidate genes and plasma concentrations of lipids, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] few have involved sufficient cases of CHD to assess reliably the relationships between polymorphisms of these genes and disease risk. Moreover, no previous study has been large enough to determine whether any differences in the risk of CHD associated with these 'lipid-related' genotypes are commensurate with their effects on plasma lipid concentrations.
In the present study, comparisons among 3460 control individuals free of cardiovascular disease yielded the associations between different genotypes for each of six lipid-related polymorphisms and the measured plasma apoB/apoA 1 ratio. Case-control comparisons involving 4685 patients with confirmed myocardial infarction (MI) and these 3460 controls provided reliable estimates of the associations between genotype and MI risk. Finally, adjustment for the plasma apoB/apoA 1 ratio yielded estimates of the associations of genotype with risk among individuals at a given level of plasma lipoproteins.
Methods

Study population
The design of the ISIS genetic study has been described in detail elsewhere. 18 Blood was collected from patients living in the UK within 24 hours of the onset of suspected acute MI. 19 A few months after hospital discharge, information was sought from surviving cases about various aspects of their lifestyle. A similar questionnaire was then sent to their siblings and children aged over 30, and to spouses of such relatives, with blood sought from those first-degree relatives and spouses who completed the questionnaire. 18, 20 Cases genotyped in this study were males aged 30-54 and females aged 30-64, with MI confirmed by cardiac enzyme and/or electrocardiographic criteria. Genotyped controls were aged 30-64 with no history of MI, angina, or other definite heart disease. Among the 6002 controls, all 1923 women and 1537 of the men were related only by marriage to first-degree relatives of MI cases in ISIS, while a further 2542 male controls were siblings or adult sons of such cases. The analyses in the present report involve only those controls who were not first-degree relatives of cases (i.e. spouses only), but subsidiary analyses based on all controls were also conducted (see below). Ethnicity was not recorded, but the family-based recruitment strategy should have yielded similar distributions among the cases and controls (and, based on other studies conducted by us in these UK hospitals during the 1990s, more than 95% would be expected to be Caucasian 21 ).
Laboratory methods
DNA was extracted from frozen buffy-coat samples, as previously described. 18 Six polymorphisms of four candidate genes coding for proteins involved in lipid metabolism were genotyped: apolipoprotein E (APOE) ε2/ε3/ε4; apolipoprotein B (APOB) Asn4311Ser and Thr71Ile; cholesteryl ester transfer protein (CETP) TaqIb; and lipoprotein lipase (LPL) Asn291Ser and T4509C (PvuII). Published primer pairs and conditions were used for PCR amplification of genomic DNA, followed by either allele-specific oligonucleotide hybridisation or restriction enzyme digestion and agarose gel electrophoresis. 12,22-25 DNA extraction and genotyping were carried out without knowledge of disease status, with samples both from cases and from controls distributed within each of the 96-well genotyping plates. Internal controls were used to check consistency of genotyping between plates. Beckman (Brea, CA, USA) autoanalysers measured plasma concentrations (in g/l) of apolipoproteins A 1 and B (using Immuno [Vienna, Austria] reagents), with an initial blank reading subtracted from the final reading to correct for any discoloration from haemolysis. 26 Samples from a large plasma pool were included in each analytical run, yielding coefficients of variation of 4% for each apolipoprotein. Repeat samples were obtained from 1038 controls at 2-3 years after the first sample, and the selfcorrelations between the measured plasma apolipoprotein values in the original and the repeat samples were used to help take appropriate account of regression dilution when calculating the effects on risk of long-term differences in the 'usual' plasma apoB/apoA 1 ratio (see below). 27, 28 Statistical analysis MI risk is positively associated with plasma levels of apolipoprotein B and negatively associated with apolipoprotein A 1 levels, and the apoB/apoA 1 ratio embodies both of these effects simply in a single statistic. In the paired samples from 1038 controls, this ratio was found to have a higher selfcorrelation (R BA = 0.820) than plasma apolipoprotein B or A 1 (0.747 and 0.679 respectively) considered on their own. As a consequence, it should tend to produce less underestimation of associations of MI risk with long-term usual plasma levels of apolipoproteins. The associations between genotypes and the plasma apoB/apoA 1 ratio in the unrelated controls were calculated using linear regression. The age-and sex-adjusted MI (Table 1) . Among the controls, there were no significant differences between the observed genotype frequencies and those expected under Hardy-Weinberg equilibrium, with the exception of the lipoprotein lipase (LPL) Asn291Ser polymorphism (at which 4 of 3332 successfully genotyped controls were homozygous for the rare serine (Ser) allele compared with 1 predicted from the allele frequencies; this small absolute discrepancy does not suggest large-scale genotyping error). Nor were there any clear associations among the controls between genotypes at any of the polymorphisms and a variety of non-lipid risk factors for CHD, with the possible exception of LPL T4509C and diabetes incidence (P = 0.003; Table 2 ). However, the incidence of diagnosed diabetes was low, and the apparent trend towards a higher incidence with the C allele of this polymorphism reflected only small absolute differences between genotypes.
Association between genotypes and plasma lipid levels
Among the 3460 unrelated controls, all of the genotyped polymorphisms-with the exception of LPL T4509C-had significant effects on plasma concentrations of apolipoprotein A 1 or apolipoprotein B, or both (Table 3) . For the apolipoprotein E (APOE) ε2/ε3/ε4 polymorphism, there were three common genotypes (ε3/ε2, ε3/ε3 and ε3/ε4; only 6.1% of cases and 5.4% of controls had the other genotypes), and the analysis considered only these three genotypes. Clear stepwise trends in the plasma concentrations of apolipoprotein A 1 and apolipoprotein B were observed between these three genotypes, with the APOE ε2 allele associated with a lower apoB/apoA 1 ratio and the ε4 allele associated with a higher apoB/apoA 1 ratio (+0.082 [s.e. 0.007] per allele change; P Ͻ 0.0001). The other polymorphisms studied were diallelic, and the primary analyses involved tests for trend across the three possible genotypes at each polymorphism. The serine (Ser) allele of the apolipoprotein B (APOB) Asn4311Ser polymorphism was associated with a lower apoB/apoA 1 ratio (Ϫ0.017 [s.e. 0.007] per Ser allele; P = 0.02); the isoleucine (Ile) allele of the APOB Thr71Ile polymorphism was associated with a higher apoB/apoA 1 ratio (+0.021 [s.e. 0.006] per Ile allele; P = 0.0009); the B2 allele of the cholesteryl ester transfer protein (CETP) TaqIb polymorphism was associated with a lower apoB/apoA 1 ratio (Ϫ0.025 [s.e. 0.006] per B2 allele; P Ͻ 0.0001); and the rare Ser allele of the LPL Asn291Ser polymorphism was associated with a higher apoB/apoA 1 ratio (+0.050 [s.e.0.022] per Ser allele; P = 0.02). The associations between genotypes and plasma apoB/apoA 1 ratio in the cases were similar to those in the controls (data not shown).
Association between genotypes and MI risk
Since clear stepwise trends in the plasma apoB/apoA 1 ratio between genotypes of these polymorphisms were observed among the controls (Table 3) , tests for trend were also performed for the case-control comparisons of genotypes and MI risk risk ratios comparing different genotypes were calculated from the case-control comparisons using logistic regression, fitted by unconditional maximum likelihood. The impact of adjusting the associations between genotype and MI risk for the measured level of the apoB/apoA 1 ratio was assessed using straightforward regression without correction for regression dilution bias. Subsidiary analyses were conducted (1) with adjustment for the estimated 'usual' levels of the apoB/apoA 1 ratio by augmenting the effect of adjustment by the factor 1/R BA , 27, 28 and (2) with adjustment for separate values of measured apolipoprotein B and apolipoprotein A 1 . Floating absolute risks and CI were used in order to share the variances of the log risk ratios appropriately between the different genotypes. 29 The analyses included all 1923 female controls but only those 1537 male controls who were unrelated to an MI case except by marriage (with adjustment for age as a continuous variable), and are given with 95% CI. (Subsidiary analyses involving both unrelated and related controls found similar associations, albeit with slightly smaller standard errors due to the larger numbers: available on request.) Analyses of genotype associations with MI risk within various subgroups (e.g. with respect to sex, age, smoking, and alcohol consumption) are given with 99% CI to make some allowance for their exploratory nature. Among the cases of confirmed MI, the log-rank test was used to test for differences between genotypes in 6-month survival after admission to hospital (chiefly to exclude the possibility that case fatality rates might differ sufficiently to bias case-control comparisons in this retrospective study).
Results
The 4685 cases of confirmed MI had an average age of 50.5 years (Table 1) , with 3052 male cases aged 30-54 and 1633 (Table 4 ). Figure 1 shows the age-and sex-adjusted MI risk ratio for each genotype plotted against the mean plasma apoB/apoA 1 ratio observed for each genotype among the controls. The casecontrol comparison yielded an age-and sex-adjusted risk ratio for MI of 1.63 (95% CI: 1.58, 1.68; P Ͻ 0.00001) per 0.10 higher usual apoB/apoA 1 ratio, which is depicted by the broken sloping line in each panel of Figure 1 (additional adjustment for smoking and BMI lowered this hazard ratio to 1.48). Hence, this figure provides a visual comparison between the differences in MI risk observed between genotypes and what might have been expected given both the genotype-associated differences in plasma apoB/apoA 1 ratio and the age-and sex-adjusted association between plasma apoB/apoA 1 ratio and MI risk.
For the APOE polymorphism, individuals with the ε3/ε2 genotype had the lowest MI risk and those with the ε3/ε4 genotype had the highest risk, while those with the ε3/ε3 genotype had intermediate risk; yielding a risk ratio of 1.16 (95% CI: 1.06, 1.27) per stepwise change in genotype (trend P-value = 0.001: Table 4 ). Figure 1 indicates that the direction of these effects of genotype on MI risk is consistent with the direction of the effects of genotype on the plasma apoB/apoA 1 ratio, but that the magnitude is smaller than expected. By contrast, although individuals with the less common Ser allele of the APOB Asn4311Ser polymorphism had a more favourable plasma apoB/apoA 1 ratio, there was a borderline significant trend for them to have a higher risk of MI [risk ratio = 1.08 (95% CI: 0.99, 1.18) per Ser allele; P = 0.08], and thus there was an apparent discrepancy between the effects of the polymorphism on plasma apoB/apoA 1 ratio and its effects on risk. Despite statistically significant associations between the measured plasma apoB/apoA 1 ratio and genotypes of the APOB Thr71Ile, CETP TaqIb, and LPL Asn291Ser polymorphisms (Table 3) , there were no significant associations of these genotypes with MI risk (Table 4) . Thus, when MI risk is plotted against apoB/apoA 1 ratio, there is a similar, though less marked, discrepancy between the observed effects of these polymorphisms on MI risk and the effects on risk that might have been expected from their effects on plasma lipoprotein levels ( Figure 1 ). Figure 2 does not indicate strong evidence of heterogeneity between the MI risk ratios associated with each of these polymorphisms for men versus women, for those at younger versus older ages, for smokers versus non-smokers, or for drinkers of alcohol versus non-drinkers, with the possible exception of alcohol consumption and the LPL Asn291Ser polymorphism. Only small numbers of individuals had the rare Ser allele of this polymorphism, so this apparent heterogeneity of effect on risk may reflect the play of chance (especially when allowance is made for multiple comparisons). Differences between genotypes in case-fatality rates following MI could potentially bias the case-control comparisons in this retrospective study. Sixmonth follow-up of the cases did not, however, indicate any significant differences in mortality following admission to hospital (data not shown). Nor was there any suggestion that the genotype frequencies differed between patients who were admitted soon after the onset of MI and those who were admitted later after symptom onset, which might have been expected if the early case fatality rates differed substantially (data not shown).
Association between genotypes and MI risk given plasma apolipoprotein concentrations
If the effects of a polymorphism on MI risk are mediated chiefly through differences in particular lipid fractions that are closely correlated with the plasma concentrations of apolipoproteins A 1 and B, then adjustment for differences between genotypes in the long-term usual plasma levels of these apolipoproteins would be expected to yield risk ratios compatible with unity. On the other hand, these adjusted risk ratios would be expected to differ from unity if the polymorphism influences risk-at least in partthrough some other mechanisms. Table 5 illustrates the impact of such adjustment, and is restricted to those cases and controls with apolipoprotein measurements. For the APOE polymorphism, each stepwise change between the ε3/ε2, ε3/ε3, and ε3/ε4 genotypes was associated with a significantly higher plasma apoB/apoA 1 ratio and higher risk of MI, but the magnitude of this effect of the polymorphism on risk was smaller than would have been predicted from the magnitude of its effect on lipoprotein levels ( Figure 1 ). Hence, after adjustment for a single measure of the plasma apoB/apoA 1 ratio, the direction of the MI risk ratio for each stepwise change in genotype reversed to 0.83 (95% CI: 0.74, 0.92; P Ͻ 0.001); with similar results when adjusted for the separate apolipoprotein values (Table 5) . For the APOB Asn4311Ser polymorphism, the Ser allele was associated with a significantly lower plasma apoB/apoA 1 ratio but a non-significantly higher risk of MI. After adjustment for the measured plasma apoB/apoA 1 ratio, however, the Ser allele was associated with a significantly higher risk of MI [risk ratio = 1.18 (95% CI: 1.07, 1.31) per Ser allele; P = 0.001]. Similarly, for the APOB Thr71Ile polymorphism, the Ile allele was not associated with a significantly higher MI risk despite a significantly higher plasma apoB/apoA 1 ratio. Hence, after adjustment for the measured apoB/apoA 1 ratio, the Ile allele was associated with a significantly lower risk of MI [risk ratio = 0.86 (95% CI: 0.79, 0.95) per Ile allele; P = 0.002]. For the CETP TaqIb polymorphism, the B2 allele was associated with a significantly lower plasma apoB/apoA 1 ratio but not with a significantly lower risk of MI. After adjustment for the measured plasma apoB/apoA 1 ratio, the B2 allele was associated with a borderline significantly higher risk of MI [risk ratio = 1.08 (95% CI: 0.99, 1.18) per B2 allele; P = 0.09]. For the LPL Asn291Ser polymorphism, few individuals had the rare Ser allele that was associated with a higher plasma apoB/apoA 1 ratio, and adjustment for a single measure of this ratio did not significantly Figure 1 Associations of genotype with risk of myocardial infarction (MI), and with ratio of apolipoprotein B to apolipoprotein A 1 . For each polymorphism, the age and sex-adjusted risk ratios (and their 95% CI) for each genotype (from Table 4 ) are plotted on a logarithmic scale against the apoB/apoA 1 ratio observed with that genotype among the controls (from Table 3 ). The age and sex-adjusted relationship between MI risk and the usual plasma apoB/apoA 1 ratio from the case-control comparison (independent of genotype) is represented by the slope of the broken line (which is positioned to go through the genotype arbitrarily assigned a risk ratio of 1.00 in Table 4 change the MI risk ratio. Finally, the LPL T4509C (PvuII) polymorphism did not appear to influence either the plasma apoB/apoA 1 ratio or MI risk, so adjustment for the measured apoB/apoA 1 ratio did not make any difference to the risk ratio.
These adjustments involved only a single measurement of plasma apolipoprotein A 1 and B in each individual, which will tend to underestimate the relevance of long-term 'usual' differences in apolipoprotein levels because of random errors in their measurement. 27, 28 Analyses of the impact of adjustment for estimated usual levels of the plasma apoB/apoA 1 ratio on the risk ratio for MI per allele change were performed. But, as a consequence of the high self-correlation coefficient for the apoB/apoA 1 ratio (Methods), risk ratio adjusted for the estimated usual levels of the apoB/apoA 1 ratio were only slightly more extreme than those adjusted just for the measured levels of the apoB/apoA 1 ratio (Table 5) .
Discussion
The present study involves many more cases of CHD than any previous investigation of polymorphisms associated with blood lipids, and is the first to have sufficient statistical power to assess reliably the effects of some of these genotypes not just on plasma lipid concentrations but also on MI risk. The observed differences in MI risk between genotypes at some of the polymorphisms studied appear to differ from those that would have been predicted from the genotype-associated differences in plasma concentrations of apolipoproteins B and A 1 . In particular, for those genotypes that were associated with significantly adverse plasma lipid profiles (in terms of the apoB/apoA 1 ratio), the adverse differences in MI risk were not as extreme as would have been expected from the differences in plasma apolipoprotein concentrations. Hence, at a given apoB/apoA 1 ratio, individuals with these apparently adverse genotypes would actually be at lower-rather than at higher-risk of MI.
Previous studies
Other studies have reported associations of these genotypes with plasma lipid concentrations that are of similar strength to those found in the present study. 8, 9, 12, 13, 25, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] The observed association of the APOE ε2/ε3/ε4 genotype with MI risk is also Previous studies have also found the two APOB polymorphisms that we investigated to be associated with differences in plasma apolipoprotein B levels, although none had reliably assessed the association between genotypes at these polymorphisms and MI risk. The present study confirms, with much narrower confidence limits, the genotype-associated differences in apolipoprotein B levels. The two APOB polymorphisms studied are in tight linkage disequilibrium (with the Ser allele of the Asn4311Ser polymorphism occurring mainly on chromosomes also bearing the Ile allele of the Thr71Ile polymorphism), and each was associated with significant differences in the plasma apoB/apoA 1 ratio among controls in the present study. But, among individuals with the same plasma apolipoprotein concentrations, these genotypes were found to be associated with MI risk in a direction that is opposite to what might have been expected from their effects on plasma lipid concentrations.
The potentially misleading effects of inadequate sample sizes in previous studies may have been further aggravated by unduly selective emphasis on the apparent results in particular subgroups. For example, one study tested the Ile405Val polymorphism of CETP in 1446 CHD cases, and found no apparent effect of the polymorphism on either plasma HDL cholesterol or CHD among men. 50 By contrast, among premenopausal women and postmenopausal women in that study who were not taking hormone replacement therapy, it was reported that carriers of the valine (Val) allele had higher HDL cholesterol levels and, in the postmenopausal subgroup, a higher incidence of CHD (odds ratio = 1.65; 95% CI: 1.06, 2.58). But, there were only 424 female cases in that study and an even smaller number in the postmenopausal subgroup alone. Similarly, in another study only 576 individuals, the Val allele of the Ile405Val polymorphism was associated with higher HDL levels, overall but with a higher CHD risk only in a retrospectively selected subgroup of 47 hypertriglyceridaemic cases. 51 Such retrospective emphasis on apparently extreme results in relatively small subgroups may well not be reliable. 18, 52 Selective survival
The present study involved cases who had survived sufficiently long from the onset of MI to be admitted to hospital. As MI carries a significant early mortality, there is the potential for survivor bias in the case ascertainment for such a retrospective study. But, whereas none of these genotypes appeared to have large effects on the risk of non-fatal MI, there would need to be a substantial effect of genotype on the risk of fatal MI to produce any material bias in these case-control comparisons. There were, however, no significant differences between the genotype frequencies of patients who were admitted within just a few hours of symptom onset and those who were admitted later. Nor did mortality rates during the 6 months following admission to hospital differ significantly between genotypes. Consequently, it does not seem likely that the present findings have been materially influenced by genotype-associated differences in case-fatality rates. A prospective study would avoid the potential for such survivor bias, but it would need to involve hundreds of thousands of healthy individuals followed for several years in order to yield similar number of cases of premature MI (and, hence, similar statistical power).
Potential confounding factors
Differences in plasma lipid concentrations are important determinants of MI risk, so it is perhaps surprising that the relationships between genotypes and risk in the present study were, in general, weaker than would have been expected given the relationships between genotypes and plasma lipoprotein levels, and between plasma lipoprotein levels and disease risk. Various explanations can be considered, though none is clearly correct. First, the strength of the relationship between the apoB/apoA 1 ratio and MI risk may have been overestimated in our data due to some effect of confounders, and the gene-disease associations may accurately reflect the contribution to risk of the corresponding genetically determined differences in plasma apolipoprotein concentrations. Although this is possible, adjustment for the available potential confounding non-lipid risk factors only accounted for a part of these discrepancies. For example, whereas adjustment for recorded smoking and BMI reduced the estimate of risk per 0.1 g/L higher plasma apoB/apoA 1 ratio from 1.63 to 1.48, differences between APOE (Figure 1 ). Second, genetic factors act during development as well as in adult life, and if the genetically determined differences in the apoB/apoA 1 ratio during adult life are also present during development then there might be some adaptation to them that limits their later effects on the incidence of MI. Third, there may be-as yet unclearbiological reasons for these quantitative discrepancies, such as pleiotropic effects of these polymorphisms (or polymorphisms in tight linkage disequilibrium with them) on factors other than plasma lipid concentrations. For example, the apolipoprotein E molecule has many biological activities that might be relevant to the development and rupture of atherosclerotic plaques, including antioxidant properties, inhibition of platelet aggregation, and modulation of inflammatory cytokine release. [53] [54] [55] [56] [57] The ε2 allele of the APOE polymorphism is also associated with delayed clearance of atherogenic remnant lipoproteins, which may offset the benefits of lower apolipoprotein B and higher apolipoprotein A 1 concentrations. 54
Mendelian randomization
It has previously been suggested that comparisons of the relationships between genotype, intermediate phenotype, and disease risk might allow the approach of 'Mendelian randomization' to identify causal associations between hypothesized novel risk factors and particular diseases. 58, 59 Among the necessary conditions for such an approach to be unconfounded is that differences between genotypes at polymorphisms of interest produce differences only in the levels, rather than in the biological function, of the risk factor. In the present study, however, the polymorphisms were either coding polymorphisms (as in the case of APOB) that might affect the biological function of the protein, or they were related to plasma apolipoprotein concentrations via complex intermediary pathways. Thus, genotypes at these polymorphisms may well influence not only the plasma concentrations of the apolipoproteins, but also the atherogenicity of the plasma at given apolipoprotein concentrations. The apparent discrepancies in the present study between the genotypeassociated disease risks and those anticipated from the observed differences in apolipoprotein concentrations should not, therefore, be interpreted as a failure of the 'Mendelian randomization' approach. Rather, these findings suggest that further investigation of the effects of these polymorphisms on more detailed lipid phenotypes (such as LDL particle size and density, triglycerides, remnant lipoprotein metabolism, and HDL subfraction concentrations) may provide important information about the ways in which these genes influence atherogenesis.
Genetic risk prediction
Whatever the explanation(s) may be, however, these discrepancies do have apparently paradoxical consequences for genetic risk prediction. For, at given plasma lipoprotein concentrations, genotypes that adversely affected lipoprotein levels actually involved a lower-rather than a higher-risk of MI. So, for example, among individuals with similar plasma lipoprotein concentrations, the presence of the CETP TaqIb B1/B1 genotype did not-by contrast with a previous suggestion 60 identify individuals at higher risk who might require particularly aggressive management. Instead, these individuals were at slightly lower risk than would have been expected from their lipid profile alone. More generally, the present findings emphasize the need to assess the relevance of genes to disease risk directly in studies involving very much larger numbers of cases than has hitherto been customary (especially if gene-gene and gene-environment interactions are to be assessed appropriately reliably), rather than just extrapolating from the observed effects of genotypes on plasma lipoprotein levels, or on other single traits that lie on (or close to) a causal pathway to disease.
